Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting

Share this story with your network

Used in 40 Surgeries To Date, MagniFuse Products Addressing Unmet Needs in Three Spinal Surgery Areas; FacetLinx(TM) Fusion Technology and Plexur M(TM) Innovative Grafting Also Featured

SAN FRANCISCO, Nov. 11 /PRNewswire-FirstCall/ — Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic products for regenerative healing, today announced it is highlighting three procedure-specific MagniFuse(TM) bone grafting products for different spine therapy areas at the North American Spine Society (NASS) 2009 Annual Meeting, taking place November 10th through 14th in San Francisco,
California. To date MagniFuse has been used in 40 spinal surgeries in the United States.

“Our strategy is to utilize our platform technologies to develop procedure-specific products to address critical unmet surgical needs and we are very excited to be highlighting our MagniFuse platform at NASS,” said Sam Owusu-Akyaw, Osteotech’s President and Chief Executive Officer. “By utilizing our MagniFuse product line in posterior cervical, posterolateral and spinal deformity procedures, Osteotech is targeting a significant segment of the spinal therapy area. Feedback from surgeons that have used MagniFuse to date indicates the differentiated characteristics and capabilities supported by our MagniFuse technology have been well received, and we believe we are strongly positioned to become a market leader.”

MagniFuse is a patented, next-generation technology platform that supports a family of high-performance, procedure-specific products that provide for simplified, precision grafting when injury or disease creates a need for bone fusion or new bone growth.

“In addition, we are also looking forward to showcasing our leading-edge FacetLinx(TM) Fusion Technology and Plexur M(TM) Innovative Grafting at NASS,” continued Mr. Owusu-Akyaw. “Similar to MagniFuse, these products have received very positive responses in the market and we believe they will both play an important role in our future success. Our goal at Osteotech is to continue to commercialize proprietary biologics designed to address the unmet needs of the surgeon community and we believe these introductions illustrate our ability to successfully execute this strategy. We are pleased to share them directly with the physician community through NASS this week.”

Leave a Comment

Your email address will not be published. Required fields are marked *

*